Biophytis (EPA:ALBPS)

REGULATED PRESS RELEASE

published on 04/15/2024 at 07:00, 1 year 11 months ago

Biophytis files a patent application and strengthens its intellectual property in obesity
Biophytis files a patent application to strengthen its intellectual property in obesity. The new patent extends BIO101's exclusivity period in treating obesity, positioning Biophytis in a fast-growing market

Biophytis Intellectual Property Clinical Trial Patent Application Obesity
BRIEF

published on 04/08/2024 at 23:17, 1 year 11 months ago

Biophytis Reports 2023 Financial Results and Business Updates

Biophytis Financial Results 2023 Sarcopenia BIO101 COVID-19 Treatment
BRIEF

published on 04/08/2024 at 23:15, 1 year 11 months ago

Biophytis Initiates Phase 2 Clinical Study for Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 GLP-1 Receptor Agonists OBA Phase 2 Study
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 1 year 11 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 1 year 11 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
BRIEF

published on 04/08/2024 at 23:09, 1 year 11 months ago

Biophytis announces its 2023 financial results and provides an update on its activities

Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF

published on 04/08/2024 at 23:05, 1 year 11 months ago

Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
PRESS RELEASE

published on 04/08/2024 at 23:04, 1 year 11 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 1 year 11 months ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 1 year 11 months ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation

Published on 03/20/2026 at 23:00, 1 day 18 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 1 day 20 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 1 day 20 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 4 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 5 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/22/2026 at 12:23, 5 hours 35 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 19 hours ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 20 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 20 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 1 day 20 hours ago

BRP Unveils the Winners of its 6th International Design Challenge

View all EQS

Published on 03/20/2026 at 19:00, 1 day 22 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 1 day 23 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 2 days ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 2 days 1 hour ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 2 days 23 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News